Patents by Inventor Michael Spedding

Michael Spedding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL USE OF A MODULATOR OF GLUCOSYLCERAMIDE DEGRADATION FOR VIRAL INFECTIONS
    Publication number: 20230233488
    Abstract: A modulator of glucosylceramide degradation and pharmaceutical compositions containing the same. Also, the use of the modulator of glucosylceramide degradation and pharmaceutical compositions containing the same in the treatment or the prevention of viral infections and disorders associated to the viral infections, such as Zika infection, dengue infection, influenza infection and coronavirus infection.
    Type: Application
    Filed: June 21, 2021
    Publication date: July 27, 2023
    Applicant: SPEDDING RESEARCH SOLUTIONS, SAS
    Inventors: Michaël SPEDDING, Rushika Michelle PERERA, Laura Athelle ST. CLAIR
  • INHIBITORS OF GLUCOSYLCERAMIDE DEGRADATION IN THE TREATMENT OF DISEASES OF THE MOTOR UNITS
    Publication number: 20210077453
    Abstract: Inhibitors of glucosylceramide degradation, to pharmaceutical compositions containing same and to the use of same in the treatment of diseases of the motor units, such as amyotrophic lateral sclerosis.
    Type: Application
    Filed: September 29, 2020
    Publication date: March 18, 2021
    Inventors: Michael SPEDDING, Alexandre HENRIQUES, Jean-Philippe LOEFFLER
  • INHIBITORS OF GLUCOSYLCERAMIDE DEGRADATION IN THE TREATMENT OF DISEASES OF THE MOTOR UNITS
    Publication number: 20190142782
    Abstract: Inhibitors of glucosylceramide degradation, to pharmaceutical compositions containing same, and to the use of same in the treatment of diseases of the motor units, such as amyotrophic lateral sclerosis.
    Type: Application
    Filed: April 11, 2017
    Publication date: May 16, 2019
    Inventors: Michael SPEDDING, Alexandre HENRIQUES, Jean-Philippe LOEFFLER
  • Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them
    Patent number: 8778932
    Abstract: Compounds of formula (I): wherein: R1 represents a hydrogen atom or an alkyl group; R2 represents an alkyl group; R3 represents an aryl or heteroaryl group. Medicinal products containing the same which are useful in the treatment or prevention of psychiatric and neurological disorders characterized by cognitive deficits.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: July 15, 2014
    Assignees: Les Laboratoires Servier, Egis Gyogyszergyar Nyrt
    Inventors: István Ling, József Barkóczy, Ferenc Antoni, István Gascályi, György Lévay, Michael Spedding, László Hársing
  • DIHYDRO-OXAZOLOBENZODIAZEPINONE COMPOUNDS, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20120232065
    Abstract: Compounds of formula (I): wherein: R1 represents a hydrogen atom or an alkyl group; R2 represents an alkyl group; R3 represents an aryl or heteroaryl group. Medicinal products containing the same which are useful in the treatment or prevention of psychiatric and neurological disorders characterised by cognitive deficits.
    Type: Application
    Filed: March 7, 2012
    Publication date: September 13, 2012
    Applicants: EGIS GYOGYSZERGYAR NYRT, LES LABORATOIRES SERVIER
    Inventors: István LING, József BARKÓCZY, Ferenc ANTONI, István GACSÁLYI, György LÉVAY, Michael SPEDDING, László HÁRSING
  • Naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them
    Patent number: 7947852
    Abstract: Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, X represents a group N—OR2 wherein R2 represents a hydrogen atom or an alkyl group. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: May 24, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Said Yous, Mohamed Ettaoussi, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
  • NAPHTHALENE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20100168244
    Abstract: Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, X represents a group N—OR2 wherein R2 represents a hydrogen atom or an alkyl group. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.
    Type: Application
    Filed: July 1, 2008
    Publication date: July 1, 2010
    Applicant: LESS LABORATOIRES SERVIER
    Inventors: Said Yous, Mohamed Ettaoussi, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
  • NAPHTHALENE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20100137446
    Abstract: Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, R2 represents a fluorine atom or an alkyl group substituted by one or more fluorine atoms. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.
    Type: Application
    Filed: July 1, 2008
    Publication date: June 3, 2010
    Inventors: Said Yous, Mohamed Ettaoussi, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
  • Naphthalene compounds
    Patent number: 7462741
    Abstract: A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: December 9, 2008
    Assignee: Les Laboratoires Servier
    Inventors: Said Yous, Basile Peres, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
  • Naphthalene compounds
    Patent number: 7435850
    Abstract: A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: October 14, 2008
    Assignee: Les Laboratoires Servier
    Inventors: Said Yous, Basile Peres, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
  • Use of agomelatine in obtaining medicaments intended for the treatment of periventricular leukomalacia
    Publication number: 20080125493
    Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of periventricular leukomalacia.
    Type: Application
    Filed: November 19, 2007
    Publication date: May 29, 2008
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Michael Spedding, Elisabeth Mocaer
  • Naphthalene compounds
    Publication number: 20080004348
    Abstract: A compound selected from those of formula (I): wherein: R1 represents a group R4 or NHR4, wherein R4 is as defined in the description; R2 represents a substituted linear or branched (C1-C6)alkyl group; R3 represents a hydrogen or halogen atom or a linear or branched (C1-C6)alkyl or linear or branched (C2-C6)alkenyl group. Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.
    Type: Application
    Filed: June 27, 2007
    Publication date: January 3, 2008
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Said Yous, Basile Peres, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Matthieu Desroses, Jean-Albert Boutin, Valerie Audinot
  • Naphthalene compounds
    Publication number: 20080004350
    Abstract: A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.
    Type: Application
    Filed: June 29, 2007
    Publication date: January 3, 2008
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Said Yous, Basile Peres, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
  • Naphthalene compounds
    Publication number: 20080004349
    Abstract: A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.
    Type: Application
    Filed: June 28, 2007
    Publication date: January 3, 2008
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Said Yous, Basile Peres, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
  • N-benzylpiperazine compounds
    Patent number: 6686360
    Abstract: The present invention relates to a compound selected from those of formula (I): wherein: R1 represents alkyl, R2 represents hydroxy, alkoxy, or amino, n represents an integer from 1 to 12 inclusive, R3 represents: hydrogen, optionally substituted alkyl, cycloalkyl, pyrimidinyl or optionally substituted phenyl, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, medicinal products containing the same are useful in the prevention or treatment of acute and chronic cell ischaemia.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: February 3, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Serge Labidalle, Jean-Paul Tillement, Bernard Testa, Roméo Cecchelli, Alain Le Ridant, Catherine Harpey, Michael Spedding, Esther Schenker
  • N-benzylpiperazine compounds
    Publication number: 20030158207
    Abstract: The present invention relates to a compound selected from those of formula (I): 1
    Type: Application
    Filed: July 16, 2002
    Publication date: August 21, 2003
    Inventors: Serge Labidalle, Jean-Paul Tillement, Bernard Testa, Romeo Cecchelli, Alain Le Ridant, Catherine Harpey, Michael Spedding, Esther Schenker
  • Use of tianeptine in the production of medicaments to treat neurodegenerative pathologies
    Patent number: 6599896
    Abstract: The invention relates to the use of tianeptine or enantiomers thereof in obtaining medicaments for use in the treatment of neurodegenerative pathologies.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: July 29, 2003
    Assignee: Les Laboratoires Servier
    Inventors: Antoine Deslandes, Michael Spedding
  • Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
    Patent number: 5733871
    Abstract: Intravenous administration and pharmaceutically acceptable compositions of neurotrophic factors for treating neuronal damage in the central nervous system of individuals in need of such treatment are disclosed. The neuronal damage associated with ischemia, hypoxia, or neurodegeneration may result from stroke or cardiac arrest. This invention provides for the intravenous administration of neurotrophic factors such as bFGF, aFGF, NGF, CNTF, BDNF, NT3, NT4, IGF-I and IGF-II.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: March 31, 1998
    Assignee: The General Hospital Corporation
    Inventors: Brian J. Alps, Christine Mary Brown, Franklin D. Collins, Caroline J. Emmett, Michael Spedding, Deborah Russell, Seth P. Finklestein, Michael A. Moskowitz, Roger Lewis Whiting
  • Isoindolinyl derivatives
    Patent number: 5726197
    Abstract: Compounds of the Formula: ##STR1## wherein: R.sup.1 and R.sup.2 are independently hydrogen or lower alkyl;R.sup.3 is hydrogen, lower alkyl, lower alkoxy, hydroxy, halo, optionally substituted phenyl, amino, nitro or trifluoromethyl; andX is --NH--, --O-- or --S--;and the pharmaceutically acceptable salts thereof exhibit high affinity and selectivity for imidazoline receptors, and are are particularly useful for modification of the female reproductive cycle.
    Type: Grant
    Filed: November 2, 1992
    Date of Patent: March 10, 1998
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Robin D. Clark, Michael Spedding
  • Benzothiadiazine compound
    Patent number: 5536719
    Abstract: A compound of formula (I): ##STR1## in the form of its S enantiomer, its addition salts with a pharmaceutically acceptable acid or base and medicinal product containing the same are useful for the treatment or prevention of pathologies associated with dysfunction of glutamatergic neurotransmission.
    Type: Grant
    Filed: July 11, 1995
    Date of Patent: July 16, 1996
    Assignee: Adir et Compagnie
    Inventors: Alex Cordi, Michael Spedding, Bernard Serkiz, Jean Lepagnol, Patrice Desos, Philippe Morain